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Abstract
Background: Decoy receptor 3 (DcR3) is a soluble protein that binds to and inactivates the death ligand CD95L.
Here, we studied a possible association between DcR3 expression and prognosis in patients with renal cell car-
cinomas (RCCs). Methods: A tissue microarray containing RCC tumor tissue samples and corresponding normal
tissue samples was generated. Decoy receptor 3 expression in tumors of 560 patients was examined by immuno-
histochemistry. The effect of DcR3 expression on disease-specific survival and progression-free survival was
assessed using univariate analysis and multivariate Cox regression analysis. Decoy receptor 3 serum levels were
determined by ELISA. Findings: High DcR3 expression was associated with high-grade (P = .005) and high-stage
(P = .048) RCCs. The incidence of distant metastasis (P = .03) and lymph node metastasis (P = .002) was sig-
nificantly higher in the group with high DcR3 expression. Decoy receptor 3 expression correlated negatively with
disease-specific survival (P < .001) and progression-free survival (P < .001) in univariate analyses. A multivariate
Cox regression analysis retained DcR3 expression as an independent prognostic factor that outperformed the
Karnofsky performance status. In patients with high-stage RCCs expressing DcR3, the 2-year survival probability
was 25%, whereas in patients with DcR3-negative tumors, the survival probability was 65% (P < .001). Moreover,
DcR3 serum levels were significantly higher in patients with high-stage localized disease (P = .007) and metastatic
disease (P = .001). Interpretation: DcR3 expression is an independent prognostic factor of RCC progression and
mortality. Therefore, the assessment of DcR3 expression levels offers valuable prognostic information that could
be used to select patients for adjuvant therapy studies.
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Introduction
Renal cell carcinoma (RCC), the most lethal of all urological cancers,
account for approximately 3% of all adult malignancies [1]. The fac-
tors used to assess the prognosis of patients are mainly based on the
TNM (tumor, node, metastasis) staging system from the American
Joint Committee on Cancer (AJCC)/Union Internationale Contre
le Cancer (UICC) [2]. However, there is still an urgent need to iden-
tify more refined markers, which will allow to anticipate the clini-
cal outcome in RCCs and which could further serve as targets for
novel therapies. Given the paramount role of antiapoptotic proteins
in the development and progression of malignant tumors, apoptosis-
related proteins are promising candidates in the search for new tumor
markers. The death receptor CD95 and its ligand, CD95L, play im-
portant roles in the evolution and therapy resistance in RCCs. The
CD95/CD95L system is variably expressed in RCCs and is described
to mediate the host cytotoxic T cell–based antitumoral immune re-
sponse as well as the cytotoxic actions of an interleukin (IL) 12/IL-2
therapy [3,4]. Therefore, defects in the CD95 receptor/ligand system
are believed to contribute to the resistance against cytotoxic T cells
and against biologic therapies of RCC cells.
The decoy receptor 3 (DcR3, also known as TR6 and M68), a
soluble protein that interacts with CD95L, LIGHT, and TNF-like
molecule 1A (TL1A), is overexpressed in many types of malignan-
cies, e.g., brain tumors, colon carcinoma, and lung cancer [5–8].
Decoy receptor 3 expression has been suggested as a potential tumor
marker for the early detection of gastric carcinoma and ovarian
cancer [9,10]. However, a systematic study on DcR3 expression in
RCCs has not been published to date.
Patients and Methods
Patients
Tissue samples from 838 patients with primary RCC treated at the
Department of Urology at the University of Heidelberg between
1987 and 2005 were collected. The human tissue samples were pro-
vided by the Tumor Tissue Bank of the National Center for Tumor
Diseases Heidelberg after approval by the ethics committee of the
University of Heidelberg. Clinical follow-up was available for all
cases. Patients were prospectively evaluated every 3 months for the
first 2 years after treatment, every 6 months for the next 3 years,
and yearly thereafter [chest x-ray or thoracic computed tomographic
(CT) scan; abdominal sonography or CT scan or magnetic resonance
imaging; serum chemistry]. No adjuvant treatment of localized dis-
ease was administered. Patients with metastasized disease and with
a Karnofsky performance index of ≥80 and no medical contrain-
dications received palliative interferon-alpha– and IL-2–based immu-
notherapy. No targeted therapeutic approaches were performed.
Survival was calculated from the date of nephrectomy until last visit
or death. All tissue samples were reviewed by experienced patholo-
gists. The tumors were graded according to the four-tiered nuclear
grading system [11] and pathologically staged based on the TNM
classification (2002).
Tissue Micro Arrays
A tissue microarray containing 838 primary tumor and correspond-
ing normal tissue samples of 838 patients was created. First, represen-
tative tissue blocks were selected as donor blocks for the tissue
microarray. Sections were cut from each donor block and stained with
hematoxylin and eosin. Then, a morphologically representative region
was chosen from each of the RCC and normal renal tissue sam-
ples. Two cylindrical core tissue specimens per tumor block (di-
ameter, 0.6 mm) were punched from these regions and arrayed into
the recipient paraffin block using a semiautomatic system (Beecher
Instruments, Silver Spring, MD). In total, 19 tissue arrays were gen-
erated, each containing 200 core tissue specimens, matching 50 pa-
tients per array.
Immunohistochemistry
The tissue microarray slides were dewaxed and rehydrated using
xylene and a series of graded alcohols, followed by heat-induced antigen
retrieval using a target retrieval solution (S2031; DakoCytomation,
Glostrup, Denmark) in a pressure cooker for 10 minutes. Staining
was performed using an automated staining system (Techmate 500;
DakoCytomation) with anti–DcR3 antibody (0.01 mg/ml, RD-
1257, clone MD3B1; BioVendor, Heidelberg, Germany) or anti–active
caspase 3 antibody, clone C92-605 (5 μg/ml; BD Biosciences, San
Jose, CA) for 30 minutes, and avidin-biotin complex peroxidase tech-
nique using aminoethylcarbazole for visualization and hematoxylin
for counterstaining. In accordance with the manufacturers’ instruc-
tions, the following solutions were used: ChemMate Detection Kit
[K5003 (DakoCytomation) containing Dako REAL Link, ready-
to-use biotinylated goat antimouse and antirabbit immunoglobulins,
and Dako REAL AEC/H2O2 Substrate Solution], ChemMate Buffer
Kit (K5006; DakoCytomation), and for the reduction of nonspecific
avidin/biotin–related staining Avidin/Biotin Blocking Kit (SP-2001;
Vector Laboratories, Burlingame, CA). Specificity controls for the
anti–DcR3 antibody included colon carcinoma cells stably transfected
with a DcR3 expression plasmid. As a negative control for the immu-
nohistochemical staining procedure, the primary antibody was omitted
or an isotype control antibody (IgG1) was used, with all other experi-
mental conditions kept constant.
For the immunohistochemical semiquantitative assessment of DcR3
expression, the product of the scores of staining intensity and quantity
of immunoreactive tumor cells was calculated based on the following
scoring system: the intensity ranged from 0 = negative, 1 = low, 2 =
medium to 3 = high; the quantity comprised 0 = no expression, 1 =
positivity in less than 1%, 2 = positivity in 1% to 9%, 3 = positivity
in 10% to 50%, and 4 = positivity in more than 50%. The final
immunohistochemical score (IHS; ranging from 0 to 12) is obtained
by multiplication of the intensity score and the quantity score. The
cutoff IHS for DcR3 expression was determined after graphically de-
picting the survival curves of each of the scores separately. This analy-
sis allowed a visual demonstration of how continuous the association
was between DcR3 expression and survival time of patients. In the
case of DcR3, a distinct gap in the survival curves was observed be-
tween the IHSs <6 and ≥6 (Figure W1). This cutoff value was used in
all univariate and multivariate analyses. The arrays were independently
scored by two pathologists (S.M.-G. and W.R.) blinded to tissue anno-
tations and patient outcomes. In the few instances of discrepant scor-
ing, a consensus score was determined. Only cases with two properly
stained tumor tissue specimens (duplicates) were included in the sub-
sequent analyses. The discordance rates between the two cores regard-
ing the IHS were as follows: in 64% of cases, an identical IHS was
obtained; in 31% of cases, the discordance was ≤4 IHS units; and
in 5% of cases, the discordance was >4 IHS units. In case of discor-
dance, the average of the two IHS was used for further analysis.
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Enzyme-Linked Immunosorbent Assay
The level of DcR3 in human serum was measured by quantitative
ELISA specific for human soluble DcR3 [12]. Briefly, 100 μl of sam-
ples (50 μl of serum plus 50 μl of PBS) were added in duplicate to
wells of 96-well ELISA plates that were coated with MD3E2 capture
monoclonal antibody and blocked with 3% BSA. The standard
DcR3 protein, twofold serially diluted in 3% BSA, was also added
in duplicate to wells. Plates were incubated overnight at 4°C. After
washing, biotinylated MD3B1 detection monoclonal antibody was
incubated to wells for 2 hours at room temperature. After washing,
peroxidase-conjugated streptavidin (Vector Laboratories) was added
to the wells for 1 hour at room temperature. Color was developed
by adding TMB peroxidase substrate solution (KPL, Gaithersburg,
MD). After stopping the color reaction with 1 N H2SO4, plates were
read at an absorbance of 450 nm in an Emax ELISA plate reader.
Decoy receptor 3 levels were calculated in reference to the standard
curve (a linear graph with range from 12.5 ng/ml to 12 pg/ml and
R2 = 0.999) generated by the SOFTmax PRO 4.3.1 LS computer
program accompanying the plate reader. Both the plate reader and
the program were from Molecular Device (Sunnyvale, CA).
Fluorescence In Situ Hybridization
A DNA probe containing the human DcR3 gene was constructed
from BAC clones RP4-583P15 and CTD-3184A7 (German Re-
source Center for Genome Research, Berlin, Germany) and labeled
using the ALEXA 488 ULS kit (Invitrogen, Freiburg, Germany). De-
paraffinized slides containing RCC tissue were subjected to heat pre-
treatment in 10 mM Na-citrate, pH 8 in a microwave oven (800 W
for 10 minutes), allowed to cool down for 30 minutes, and digested
using 0.005% pepsin (Sigma, Taufkirchen, Germany) for 20 minutes
at 37°C. After rinsing in 2× SSC, slides were postfixed in 4% para-
formaldehyde, briefly rinsed in 2× SSC and H2O, and air-dried. Tis-
sue and DNA probes were codenatured in an in situ thermocycler
(Perkin Elmer, Darmstadt, Germany) at 85°C for 5 minutes, cooled
down to 37°C, and hybridized in a humid chamber overnight. After
posthybridization washing in 2× SSC, 0.3% NP-40 (at 75°C for
2 minutes), slides were briefly rinsed in H2O and coverslipped using
fluorescence mounting medium containing di-amidino-phenyl-indole
(MP, Strasbourg, France).
Statistical Methods
Data were analyzed using the R software package (version 2.5.1,
http://www.rproject.org). For count data, Fisher’s exact test (two-
sided) was used. The Kaplan-Meier method was applied to calculate
survival probabilities for both progression-free and cancer-specific
overall survival. The cuminc function in the R package cmprsk was
used to perform a competing risk analysis. For univariate and multi-
variate analyses, the Cox proportional hazards regression model was
used. Internal validation was performed using 1000 bootstrap resam-
ples. Univariate survival data were tested for significance using the
Mantel-Haenszel log rank test. The Wilcoxon rank sum test was used
to compare DcR3 serum concentrations or the percentages of apop-
totic cells with DcR3 IHSs. P < .05 were considered significant.
Results
To identify prognostic markers for RCCs in a large cohort of pa-
tients, we constructed a tissue microarray containing approximately
3500 tissue samples. Tumor tissue and corresponding normal renal
tissue samples were used from 838 patients with RCCs. Decoy recep-
tor 3 expression was analyzed using a commercially available mouse
monoclonal antihuman DcR3 antibody. A total of 560 cases was suc-
cessfully scored for DcR3 expression in two different areas of the
tumor. The remaining 278 cases with insufficient tumor tissue or
fixation artifacts were excluded from further analyses. The median
follow-up time was 40 months (mean, 55 months). At the last fol-
low-up, of 560 patients, 182 (33%) had died of RCC, 52 (9%) had
died of unrelated causes, and 326 (58%) are still alive. Table 1 pro-
vides a summary of the clinical and pathologic features.
DcR3 Expression Assessed by Immunohistochemistry
High DcR3 expression (defined as an IHS ≥6) was determined as
the cutoff level after graphically depicting the survival curves of each
of the scores separately (see Patients and Methods). High DcR3 ex-
pression was observed in 52 patients (9.3%). The subcellular expres-
sion pattern of DcR3 was mainly diffusely cytoplasmic (Figure 1, A–
G ). The normal renal tissue was negative or weakly positive for
DcR3 (Figure 1H ). No significant association was observed between
DcR3 expression and the presence of apoptotic tumor cells as as-
sessed by immunohistochemical detection of active caspase 3
(Figure W2). Using Fisher’s exact tests, high DcR3 expression levels
were significantly associated with tumor size, regional lymph node
metastasis, distant metastasis, and grade of malignancy (Table 2).
Table 1. Summary of Clinical and Pathologic Features.
Feature Number of Patients % of Patients
Sex
Male 348 62
Female 212 38
Age at surgery (median, 63 years; range, 25-89 years)
<65 years 310 55
≥65 years 250 45
Karnofsky performance status scale
≥80% 512 91
<80% 48 9
Tumor extent (TNM 2002)
pT1 304 54
pT2 59 11
pT3 186 33
pT4 11 2
Regional lymph node metastasis (TNM 2002)
N0/pN0 519 93
pN1, pN2 41 7
Distant metastasis (TNM 2002)
Yes 87 16
No 473 84
Grade of malignancy*
G1 146 26
G2 321 58
G3 87 16
G4 3 <1
Histopathologic subtype
Clear-cell (conventional) RCC 464 83
Papillary (chromophil) RCC 48 9
Chromophobe RCC 25 4
Spindle cell carcinoma 5 <1
Collecting duct carcinoma 2 <1
Unclassified RCC 16 3
Type of surgery
Partial nephrectomy 81 14
Radical nephrectomy 479 86
Treatment for metastasized disease†
Yes 25 29
No 62 71
*Three patients with tumors of unknown grade.
†Interferon-alpha– and IL-2–based immunotherapy.
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Further, DcR3-positive RCCs occurred significantly more frequently
in male patients. In contrast, there was no consistent relationship
between DcR3 expression and Karnofsky performance status or his-
topathologic subtype of the RCCs. Similarly, an association between
age at surgery and DcR3 expression was not observed using the
Wilcoxon rank sum test (P = .9; high DcR3: median age 62 years,
range 36-79 years; low DcR3: median age 63 years, range 25-
89 years). In the subgroup of patients without distant metastasis,
DcR3 expression was associated with regional lymph node metastasis
and sex. No significant associations were obtained in the subgroup of
patients with distant metastasis, possibly due to the limited number
of patients (n = 87).
Univariate survival analyses showed that high DcR3 expression is
associated with the risk of death from RCC both in the whole patient
cohort and in the group of patients with nonmetastasized disease
(M0; Figure 2, A and B). In metastatic disease (M1), a trend toward
shorter survival times (P = .08) was observed (Figure 2B). Similarly,
DcR3 was a significant prognostic factor for tumor-specific sur-
vival in the subgroups of patients with high-grade (G3/G4) RCCs
(Figure 2C ) and high-stage (T3/T4) RCCs (Figure 2D). In contrast,
DcR3 expression was not significantly associated with the cancer-
specific outcome in G1/G2 or in T1/T2 RCCs (P = .3 and P =
.4, respectively). Moreover, high DcR3 expression increased the risk
of RCC progression (n = 206) as defined by the first occurrence of
either lymph node metastasis, distant metastasis, local tumor recur-
rence, or death due to RCC (Figure W3). The hazard ratio of the
univariate Cox regression analyses was 2.1. To internally validate
the data, we performed bootstrapping analysis by resampling the
study cohort 1000 times with replacement (hazard ratio: mean,
2.1; SD, 0.49). Further, to confirm that the Kaplan-Meier method
is applicable to our setting, we performed a competing risk analysis.
Cumulative incidence curves for high and low DcR3 expression were
significantly different for tumor-specific mortality (P < .001), where-
as a significant difference was not observed regarding death due to
tumor-unrelated causes (P = .4).
Next, we investigated the impact of DcR3 expression on the RCC-
related cancer-specific survival and the progression-free survival by
multivariate analysis. Multivariate Cox regression analysis on RCC
outcome included DcR3 expression, Karnofsky performance status,
tumor size, regional lymph node metastasis, distant metastasis, grade
of malignancy, histopathologic subtype, type of surgery, and sex. This
analysis revealed that DcR3 status is an independent prognostic fac-
tor for both cancer-specific survival (Table 3) and progression-free
survival (Table W1). Apart from DcR3, tumor extent, metastatic dis-
ease, malignancy grade, and gender emerged as significant prognostic
factors, whereas the Karnofsky status, histopathologic subtype, and
type of surgery were not correlated with the clinical outcome. More-
over, we performed multivariate Cox regression analyses in the sub-
groups of patients with or without distant metastasis. Decoy receptor
3 expression was an independent prognostic factor for progression-
free survival in nonmetastasized disease (P = .04) and showed a trend
toward a shorter cancer-specific survival in metastatic disease (P =
.07; Table W2).
DcR3 Expression Assessed by ELISA and FISH
Further, we investigated serum DcR3 protein levels in an indepen-
dent cohort of RCC patients by ELISA. Decoy receptor 3 serum
levels ranged between 0.03 and 1.65 in normal controls (n = 15)
and between 0.03 and 10.14 in patients with RCCs (n = 42). Serum
DcR3 levels were significantly elevated in patients with high-stage,
nonmetastatic RCCs and in patients with metastasized RCCs com-
pared to controls (Figure 3A). In contrast, no significant difference
was observed between normal controls and low-stage, nonmetastatic
RCCs. Moreover, high DcR3 serum levels were significantly associ-
ated with high DcR3 expression in the tumor tissue as assessed by
immunohistochemistry (P = .02; Figure 3B).
To investigate the mechanisms of DcR3 overexpression in RCCs, we
assessed the DcR3 gene copy number in 20 RCC samples (high DcR3
expression, n = 10; low DcR3 expression, n = 10) by fluorescence
Figure 1. Immunohistochemical detection of DcR3 protein in RCCs
of diverse histopathologic subtypes (original magnification, ×100).
(A–D) Clear-cell (conventional) RCCs with different grades of malig-
nancy (A: G1, B: G2, C: G3, D: G4); (E) papillary (chromophil) RCC;
(F) chromophobe RCC; (G) collecting duct carcinoma; (H) normal
tubular renal tissue. The IHSs were as follows: A, 0; B, 0; C, 12; D,
12; E, 12; F, 0; G, 9.
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in situ hybridization. In these 20 tumors, DcR3 gene amplifications
were not observed.
Discussion
Renal cell carcinoma cells are known to be largely multidrug-
resistant. Apart from effective drug detoxification mechanisms and
up-regulated expression of P-glycoprotein, RCC cells exhibit a pro-
nounced resistance to CD95-mediated apoptosis, although they con-
stitutively express CD95 and CD95L [13–15]. At the same time,
CD95/CD95L interactions might constitute a key mechanism in
the process of cytotoxic T lymphocytes killing RCC cells [4]. An
elevated expression of the soluble decoy receptor for CD95L,
DcR3, may contribute to the resistance of RCC cells to death
ligand–induced apoptosis. Decoy receptor 3 is a 35-kDa protein that
lacks a transmembrane domain and that is secreted into the extra-
cellular space. Decoy receptor 3 binds to the ligands CD95L and
LIGHT, thereby neutralizing their proapoptotic actions [5,7]. Im-
portantly, DcR3 is frequently overexpressed in cancer, e.g., in malig-
nant tumors of the brain, lung, and gastrointestinal tract [5,6,16–
22]. Thus, it has been postulated that the activation of the CD95/
CD95L system limits cancer growth and, consequently, that cells
expressing higher levels of DcR3 are more likely to escape elimina-
tion. Decoy receptor 3 was prescribed an immunosuppressive role in
diverse experimental models, e.g., in DcR3 transgenic mice exhibit-
ing an attenuation of the TH1 response and a suppression of cell-
mediated immunity [23]. Moreover, DcR3 inhibits T cell chemotaxis,
down-regulates cytotoxic T lymphocyte activity in vitro and graft-
versus-host responses in mice, and modulates dendritic cell differenti-
ation and survival [24–28].
The suppression of immune responses by the above-mentioned
mechanisms as well as by counteracting CD95L-mediated activation
of apoptosis might play an important role in the evolution of RCCs.
Therefore, we examined DcR3 expression in a large collection of
human RCC samples by immunohistochemistry. In this study, we
show that DcR3 expression in RCCs correlates significantly with
the clinical outcome. In multivariate analyses including other prog-
nostic factors (such as Karnofsky performance status, tumor size, dis-
tant metastasis, and grade of malignancy), DcR3 expression was
prognostic for cancer-specific survival and progression-free survival.
Further, DcR3 expression outperformed the Karnofsky performance
status as a prognostic marker.
In addition to the tumor size and the presence of distant metastasis
(T and M within the TNM staging system), the Karnofsky perfor-
mance status score, grade of malignancy, sex, and microscopic tumor
necrosis are considered to be prognostic markers in RCCs [29,30].
Moreover, many additional molecular and biochemical tumor mark-
ers have been tested in RCCs, including lactate dehydrogenase,
Table 2. Comparison of DcR3 Expression Levels and Clinical and Pathologic Features.
Feature All Patients Without Distant Metastasis (M0) With Distant Metastasis (M1)
Low (n = 508,
91%)
High (n = 52,
9%)
P Low (n = 435,
92%)
High (n = 38,
8%)
P Low (n = 73,
84%)
High (n = 14,
16%)
P
n % n % n % n % n % n %
Sex .004 .015 .5
Male 306 55 42 8 253 53 30 6 53 61 12 14
Female 202 36 10 2 182 39 8 2 20 23 2 2
Age at surgery 1 .9
<65 years 281 50 29 5 231 49 21 4 50 57 8 9 .5
≥65 years 227 41 23 4 204 43 17 4 23 26 6 7
Karnofsky performance status scale .6 1 .4
≥80% 463 83 49 9 400 85 35 7 63 73 14 16
<80% 45 8 3 1 35 7 3 1 10 11 0 0
Tumor extent* .048 .1 .8
pT1/2 336 60 27 5 306 65 22 5 30 35 5 6
pT3/4 172 31 25 4 129 27 16 3 43 49 9 10
Regional lymph node metastasis* .002 .02 .2
N0/pN0 477 84 42 8 418 88 33 7 59 68 9 10
pN1, pN2 31 6 10 2 17 4 5 1 14 16 5 6
Distant metastasis* .03 – –
No 435 78 38 7 – – – – – – – –
Yes 73 13 14 3 – – – – – – – –
Grade of malignancy† .005 .2 .1
G1/2 430 77 35 6 386 82 30 7 44 51 5 6
G3/4 76 14 16 3 47 10 7 1 29 33 9 10
Histopathologic subtype‡ .1 .8 .06
Clear-cell RCC 425 76 39 7 362 76 30 6 63 73 9 11
Papillary RCC 42 8 6 1 36 8 5 1 6 7 1 1
Chromophobe RCC 23 4 2 <1 23 5 1 <1 0 0 1 1
Spindle cell carcinoma 3 1 2 <1 1 <1 0 0 2 2 2 2
Collecting duct carcinoma 0 0 2 <1 0 0 1 <1 0 0 1 1
Unclassified RCC 15 3 1 <1 13 3 1 <1 2 2 0 0
Type of surgery .7 .7 .2
Radical nephrectomy 433 77 46 8 360 76 33 7 73 84 13 15
Partial nephrectomy 75 14 6 1 75 16 5 1 0 0 1 1
P values < .05 are shown in bold.
*TNM 2002.
†Three patients with tumors of unknown grade.
‡Clear-cell (conventional) RCC versus other types.
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serum calcium, ferritin, p53, IL-2, and others [31–33]. Nevertheless,
more accurate and valid markers are urgently needed to allow an op-
timal patient selection for experimental adjuvant treatment strategies
and better follow-up planning. Our results suggest DcR3 as a novel
independent marker of RCC outcome. Interestingly, the apoptotic
index (i.e., the percentage of apoptotic tumor cells) was reported
to be an independent prognostic marker for overall survival in pa-
tients with RCCs [34]. Given the great importance of the CD95 sys-
tem in the development of malignant tumors, a functional link
between low apoptosis rates as well as high DcR3 expression in RCCs
and poor clinical prognosis should be considered. However, we could
not confirm an association between the presence of apoptotic tumor
cells and the expression levels of DcR3 in RCCs. Because apoptosis is
a rapidly executed process and only few cells might display features of
apoptosis (such as activation of caspase 3) at a given time point, our
results do not necessarily exclude a functional connection between
DcR3 and inhibition of apoptosis in RCCs. Alternatively, CD95-in-
dependent immunosuppressive mechanisms triggered by DcR3
might play a role, such as suppression of CD8 T cell function by
neutralization of LIGHT [35] or increased angiogenesis by neutrali-
zation of TL1A [36].
Figure 2. Analysis of cancer-specific survival depending on DcR3 expression levels. (A) All patients (n = 560). (B) Patients with nonmeta-
static disease (M0, n = 473) versusmetastatic disease (M1, n = 87). (C) Patients with high-grade RCCs (G3/G4, n = 92) versus low-grade
RCCs (G1/G2, n = 465). (D) Patients with extended primary tumor (T3/T4, n = 197) versus limited primary tumor (T1/T2, n = 363).
Table 3. Multivariate Cox Regression Analysis of DcR3 Expression and Clinical/Pathologic Fea-
tures for the Prediction of Cancer Specific Survival.
Feature Multivariate Cox Regression Analysis*
Hazard Ratio 95% CI P
DcR3 expression† 1.8 1.2-2.8 .006
Karnofsky performance status‡ 1.5 1.0-2.3 .09
Tumor extent§ 2.0 1.5-3.0 <.001
Regional lymph node metastasis¶ 1.4 0.9-2.2 .1
Distant metastasis# 5.0 3.5-7.1 <.001
Grade of malignancy** 1.8 1.3-2.6 <.001
Histopathologic subtype†† 1.1 0.7-1.7 .7
Type of surgery‡‡ 2.1 1.0-4.6 .06
Sex§§ 0.7 0.5-0.9 .02
CI indicates confidence interval.
*Three patients with tumors of unknown grade of malignancy were excluded.
†Immunohistochemical score ≥6 versus <6.
‡<80% versus ≥80%.
§pT3/pT4 versus pT1/pT2.
¶pN1/pN2 versus N0/pN0.
#M1/pM1 versus M0/pM0.
**G3/G4 versus G1/G2.
††Clear-cell (conventional) RCC versus other types.
‡‡Radical versus partial nephrectomy.
§§Female versus male.
1054 Decoy Receptor 3 in Renal Cell Carcinoma Macher-Goeppinger et al. Neoplasia Vol. 10, No. 10, 2008
Further, the present study demonstrates a higher expression of
DcR3 in male than in female patients. Although a gender-specific
expression of DcR3 has not yet been reported, it is well known that
the expression of several apoptosis-related proteins is regulated by hor-
mone receptors. For example, the antiapoptotic proteins FLIP and
protein kinase C delta are induced by androgen receptors [37,38].
Interestingly, androgen receptors are reported to be expressed in a sub-
set of RCCs [39]. Thus, a possible androgen-dependent regulation of
DcR3 expression should further be investigated.
The prognostic value of DcR3 expression might be specific for
RCCs, because studies on urothelial carcinomas of the bladder/ureter
as well as on colon carcinomas did not show a significant correlation
between DcR3 expression and patient outcome [40,41]. However,
the latter study found that amplification of the DcR3 gene was a pre-
dictive marker for the efficacy of a 5-fluorouracil–based adjuvant che-
motherapy for colon carcinomas [41]. With DcR3 serving as a
prognostic factor for RCC outcome, further investigations on the im-
pact of DcR3 expression on the success of novel treatment strategies
(e.g., targeted therapies) for RCCs are warranted.
Amplification of the DcR3 gene was described in several types of
tumors, such as lung cancer, glioblastomas, gastric carcinomas, and
colorectal cancer [5,9,17,41]. In other tumor types, a genomic am-
plification was not detectable [9,16]. We performed fluorescence
in situ hybridizations of 20 RCC tissue samples, but we did not ob-
serve DcR3 gene amplification. Therefore, other mechanisms than
genomic amplification may be responsible for the up-regulation of
DcR3 in RCCs, such as stabilization of the DcR3 protein, methyla-
tion of the DcR3 promoter, or direct transcriptional activation.
Our data suggest that the immunohistochemical detection of
DcR3 expression in RCC tissue corresponds well with DcR3 protein
levels in the serum of patients as assessed by ELISA. Therefore, the
ELISA-based measurement of DcR3 concentration in serum samples
might even be a more feasible way to obtain prognostic information.
However, the reliability of the DcR3 serum level as an independent
prognostic marker needs confirmation in a larger study.
Finally, our data open up the possibility to develop novel treat-
ment strategies based on the antagonization of DcR3. Given the
strong expression of DcR3 in high-grade and high-stage RCCs, a re-
cently described tumor vaccine approach based on cell surface ex-
pression of DcR3 might become an experimental treatment option
for patients with RCCs [42].
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Figure W1. Analysis of cancer-specific survival depending on
DcR3 expression levels. The survival curves are depicted in incre-
ments of 3 scoring units (IHS 0, 0-3, 3-6, 6-9, 9-12) of DcR3 expres-
sion as assessed by immunohistochemistry.
Figure W2. Comparison between the presence of apoptotic tumor
cells and DcR3 expression levels in RCCs (n = 82). The DcR3 ex-
pression levels are presented as IHSs. Apoptotic cell death was
assessed by the immunohistochemical detection of the active
subunit of Caspase 3 (p17) in RCC cells. Three hundred cells per
tumor sample were counted.
Figure W3. Analysis of progression-free survival depending on
DcR3 expression levels (all patients, n = 560).
Table W1. Multivariate Cox Regression Analysis of DcR3 Expression and Clinical/Pathologic Fea-
tures for the Prediction of Progression-Free Survival.
Feature Progression-Free Survival
Hazard Ratio 95% CI P
DcR3 expression* 1.9 1.2-3.0 .003
Karnofsky performance status† 1.2 0.8-1.9 .4
Tumor extent‡ 2.3 1.6-3.3 <.001
Regional lymph node metastasis§ 1.7 1.1-2.7 .02
Distant metastasis¶ 3.2 2.3-4.6 <.001
Grade of malignancy# 1.9 1.3-2.7 <.001
Histopathologic subtype** 1.3 0.8-2.1 .3
Type of surgery†† 2 0.9-4.3 .08
Sex‡‡ 0.6 0.5-0.9 .01
*Immunohistochemical score ≥6 versus <6.
†<80% versus ≥80%.
‡pT3/pT4 versus pT1/pT2.
§pN1/pN2 versus N0/pN0.
¶M1/pM1 versus M0/pM0.
#G3/G4 versus G1/G2.
**Clear-cell (conventional) RCC versus other types.
††Radical versus partial nephrectomy.
‡‡Female versus male.
Table W2. Multivariate Cox Regression Analysis of DcR3 Expression and Clinical/Pathologic Fea-
tures for the Prediction of Cancer-Specific and Progression-Free Survival in Patients with or with-
out Distant Metastasis.
Feature Without Distant Metastasis
(M0)
With Distant Metastasis
(M1)
Hazard
Ratio
95% CI P Hazard
Ratio
95% CI P
(A) Cancer-specific survival
DcR3 expression* 1.5 0.9-2.9 .1 2 0.9-4.3 .07
Karnofsky performance status† 1.1 0.6-2.0 .7 2.6 1.2-5.4 .01
Tumor extent‡ 2.5 1.6-3.9 <.001 1.2 0.7-2.1 .5
Regional lymph node metastasis§ 2.1 1.2-3.9 .008 0.6 0.3-1.3 .3
Type of surgery¶ 1.7 0.7-4.1 .2 2.2 0.2-18 .5
Grade of malignancy# 2.3 1.4-3.8 <.001 1.5 0.9-2.7 .1
Histopathologic subtype** 1.5 0.8-3.1 .2 0.3 0.1-0.7 .002
Sex†† 0.5 0.3-0.8 .004 1.2 0.6-2.2 .5
(B) Progression-free survival
DcR3 expression* 1.8 1.0-3.2 .04 1.8 0.8-4.2 .2
Karnofsky performance status† 0.7 0.4-1.4 .4 2.7 1.3-5.6 .009
Tumor extent‡ 2.8 1.8-4.3 <.001 1.5 0.9-2.5 .2
Regional lymph node metastasis§ 4.2 2.3-7.4 <.001 0.4 0.2-1.0 .04
Type of surgery¶ 1.8 0.8-4.3 .2 0.1 0.01-0.6 .02
Grade of malignancy# 2.3 1.4-3.7 <.001 2.1 1.2-3.6 .01
Histopathologic subtype** 1.9 1.0-3.7 .048 0.2 0.1-0.5 <.001
Sex†† 0.5 0.4-0.9 .009 1.0 0.6-1.8 .9
*Immunohistochemical score ≥6 versus <6.
†<80% versus ≥80%.
‡pT3/pT4 versus pT1/pT2.
§pN1/pN2 versus N0/pN0.
¶Radical versus partial nephrectomy.
#G3/G4 versus G1/G2.
**Clear-cell (conventional) RCC versus other types.
††Female versus male.
Table W3. Summary of Clinical and Pathologic Features.
Feature Number of Patients % of Patients
Tumor extent (TNM 2002)
pT1 28 67
pT2 2 5
pT3 11 26
pT4 1 2
Regional lymph node metastasis (TNM 2002)
N0/pN0 39 93
pN1, pN2 3 7
Distant metastasis (TNM 2002)
yes 2 5
no 40 95
Grade of malignancy
G1 1 2
G2 31 74
G3 10 24
G4 0 0
Table W4. Summary of Clinical and Pathologic Features.
Feature Number of Patients % of Patients
Tumor extent (TNM 2002)
pT1 9 45
pT2 1 5
pT3 9 45
pT4 1 5
Regional lymph node metastasis (TNM 2002)
N0/pN0 17 85
pN1, pN2 3 15
Distant metastasis (TNM 2002)
Yes 2 10
No 18 90
Grade of malignancy
G1 1 5
G2 13 65
G3 6 30
G4 0 0
